Features Navigation

(800) 825-0224 Live Demo
 ID NQF # Measure Type High Priority Measure? NQS Domain Data Submission Method(s)
450 1858 Process Yes Effective Clinical Care Registry

Measure Description

Percentage of female patients (aged 18 years and older) with AJCC stage I (T1c) – III, human epidermal growth factor receptor 2 (HER2) positive breast cancer receiving adjuvant chemotherapy who are also receiving Trastuzumab

Instructions

This measure is to be submitted a minimum of once per performance period for patients with breast cancer seen during the performance period. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

Measure Submission

The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data.

Numerator:

Trastuzumab administered within 12 months of diagnosis

NOTE: If Trastuzumab was not administered within 12 months of diagnosis, the presence of the denominator exception should be examined during that same time period.

Numerator Quality-Data Coding Options

Performance Met:

Trastuzumab administered within 12 months of diagnosis (G9835)

Denominator Exception:

Reason for not administering Trastuzumab documented (e. g. patient declined, patient died, patient transferred, contraindication or other clinical exclusion, neoadjuvant chemotherapy or radiation NOT complete) (G9836)

Performance Not Met:

Trastuzumab not administered within 12 months of diagnosis (G9837)

Denominator:

Adult women with AJCC stage I (T1c) – III, HER2 positive breast cancer who receive adjuvant chemotherapy

Denominator Criteria (Eligible Cases):
Female Patients aged ≥ 18 years on date of encounter

AND
Diagnosis of breast cancer (ICD-10-CM): C50. 011, C50. 012, C50. 019, C50. 111, C50. 112, C50. 119, C50. 211, C50. 212, C50. 219, C50. 311, C50. 312, C50. 319, C50. 411, C50. 412, C50. 419, C50. 511, C50. 512, C50. 519, C50. 611, C50. 612, C50. 619, C50. 811, C50. 812, C50. 819, C50. 911, C50. 912, C50. 919

AND
Patient encounter during performance period (CPT): 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215

AND
Two or more encounters at the reporting site

AND
Breast Adjuvant Chemotherapy administered: G9829

AND
HER-2/neu positive: G9830

AND
AJCC stage at breast cancer diagnosis = II or III: G9831

OR
AJCC stage at breast cancer diagnosis = I (IA or IB) and T-Stage at breast cancer diagnosis does NOT equal = T1, T1a, T1b: G9832

AND NOT
DENOMINATOR EXCLUSIONS:
Patient transfer to practice after initiation of chemotherapy: G9833

OR
Patient has metastatic disease at diagnosis: G9834

Definitions:

Use the following definitions to determine HER2 status-Positive:
IHC 3+ based on circumferential membrane staining that is complete, intense

ISH positive based on:

  • Single-probe average HER2 copy number = 6. 0 signals/cell
  • Dual-probe HER2/CEP17 ratio = 2. 0 with an average HER2 copy number = 4. 0 signals/cell
  • Dual-probe HER2/CEP17 ratio = 2. 0 with an average HER2 copy number < 4. 0 signals/cell
  • Dual-probe HER2/CEP17 ratio < 2. 0 with an average HER2 copy number = 6. 0 signals/cell

Equivocal:
IHC 2+ based on circumferential membrane staining that is incomplete and/or weak/moderate and within > 10% of the invasive tumor cells or complete and circumferential membrane staining that is intense and within = 10% of the invasive tumor cells ISH equivocal based on:

  • Single-probe ISH average HER2 copy number = 4. 0 and < 6. 0 signals/cell
  • Dual-probe HER2/CEP17 ratio < 2. 0 with an average HER2 copy number = 4. 0 and < 6. 0 signals/cell

Negative:
IHC 1+ as defined by incomplete membrane staining that is faint/barely perceptible and within > 10% of the invasive tumor cells or IHC 0 as defined by no staining observed or membrane staining that is incomplete and is faint/barely perceptible and within = 10% of the invasive tumor cells

ISH negative based on:

  • Single-probe average HER2 copy number < 4. 0 signals/cell
  • Dual-probe HER2/CEP17 ratio < 2. 0 with an average HER2 copy number < 4. 0 signals/cell

Indeterminate:
Indeterminate if technical issues prevent one or both tests (IHC and ISH) from being reported as positive, negative, or equivocal.

Conditions may include:

  • Inadequate specimen handling
  • Artifacts (crush or edge artifacts) that make interpretation difficult
  • Analytic testing failure.

Experience AdvancedMD Software in a Live Demo.

Schedule a short and personalized overview, guided by a live expert.

“The money I have invested in AdvancedMD is miniscule compared to the return. I have never been more efficient – ever – in my professional life as I am now.”

Jed Shay, MD
The Pain Care Center

Read the story  ›

“The nice thing about AdvancedMD is claims are cleared before they are forwarded to various insurance companies. We know very, very quickly if we have some defective portion on our claim.”

Dwight Romriell, DMD

Read the story  ›

“If we are waiting for a delivery or in between surgeries, we can log in, check messages or patient information and send electronic prescriptions as needed. Mobility is a good thing, and certainly being able to coordinate care with our patients from multiple locations is definitely a plus.”

Lisbeth Chang, MD
Sunrise Women’s Medical Group

Read the story  ›

“If you want to be focused on your practice and not worry about infrastructure, this is it. It’s transparent, just like when I plug something into the wall I’m not worried about what the voltage is and what’s the availability; it’s just there—like AdvancedMD. It does it so well sometimes you don’t appreciate it until you really think about it.”

Judy Feingold
Occupational Therapist